Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition.

Mitropoulou AN, Bowen H, Dodev TS, Davies AM, Bax HJ, Beavil RL, Beavil AJ, Gould HJ, James LK, Sutton BJ.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8707-E8716. doi: 10.1073/pnas.1806840115. Epub 2018 Aug 27.

2.

Anti-Folate Receptor alpha-directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer.

Cheung A, Opzoomer JW, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall MW, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder SE, Nestle FO, Gillett C, Spicer J, Grigoriadis A, Tutt A, Karagiannis SN.

Clin Cancer Res. 2018 Aug 1. pii: clincanres.0652.2018. doi: 10.1158/1078-0432.CCR-18-0652. [Epub ahead of print]

PMID:
30068707
3.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Josephs DH, Nakamura M, Bax HJ, Dodev TS, Muirhead G, Saul L, Karagiannis P, Ilieva KM, Crescioli S, Gazinska P, Woodman N, Lomardelli C, Kareemaghay S, Selkirk C, Lentfer H, Barton C, Canevari S, Figini M, Downes N, Dombrowicz D, Corrigan CJ, Nestle FO, Jones PS, Gould HJ, Blower PJ, Tsoka S, Spicer JF, Karagiannis SN.

Allergy. 2018 Apr 13. doi: 10.1111/all.13455. [Epub ahead of print]

PMID:
29654623
4.

BRAF inhibitors: resistance and the promise of combination treatments for melanoma.

Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann RM, Ilieva KM, Cheung A, Spicer JF, Papa S, Lacy KE, Karagiannis SN.

Oncotarget. 2017 Aug 3;8(44):78174-78192. doi: 10.18632/oncotarget.19836. eCollection 2017 Sep 29. Review.

5.

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Ilieva KM, Fazekas-Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J, Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN.

Front Immunol. 2017 Sep 11;8:1112. doi: 10.3389/fimmu.2017.01112. eCollection 2017.

6.

AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.

Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D, Fiebiger E, Gould HJ, Irshad S, Janda J, Josephs DH, Levi-Schaffer F, O'Mahony L, Pellizzari G, Penichet ML, Redegeld F, Roth-Walter F, Singer J, Untersmayr E, Vangelista L, Karagiannis SN.

Allergy. 2018 Feb;73(2):328-340. doi: 10.1111/all.13311. Epub 2017 Oct 5.

PMID:
28921585
7.

IgE Trimers Drive SPE-7 Cytokinergic Activity.

Bax HJ, Bowen H, Beavil RL, Chung R, Ward M, Davies AM, Dodev TS, McDonnell JM, Beavil AJ, Sutton BJ, Gould HJ.

Sci Rep. 2017 Aug 15;7(1):8164. doi: 10.1038/s41598-017-08212-6.

8.

Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.

Karagiannis SN, Josephs DH, Bax HJ, Spicer JF.

Cancer Res. 2017 Jun 1;77(11):2779-2783. doi: 10.1158/0008-5472.CAN-17-0428. Epub 2017 May 19. Review.

9.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF, Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.

10.

AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis SN.

Allergy. 2017 Jun;72(6):866-887. doi: 10.1111/all.13119. Epub 2017 Jan 23. Review.

11.

Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN.

MAbs. 2016 Nov/Dec;8(8):1437-1455. Epub 2016 Aug 5. Review.

12.

Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.

Vigor K, Emerson J, Scott R, Cheek J, Barton C, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF, Lentfer H.

Biotechnol Prog. 2016 Nov;32(6):1494-1502. doi: 10.1002/btpr.2359. Epub 2016 Oct 21.

PMID:
27604040
13.

Beta-glucan contamination of pharmaceutical products: How much should we accept?

Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF.

Cancer Immunol Immunother. 2016 Nov;65(11):1289-1301. Epub 2016 Jul 29. Review.

14.

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.

Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S, Crescioli S, Hobbs C, Villanova F, Cheung A, Geh JL, Healy C, Harries M, Sanz-Moreno V, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN.

Sci Rep. 2016 Jul 14;6:29736. doi: 10.1038/srep29736.

15.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 Aug 9;7(32):52553-52574. doi: 10.18632/oncotarget.9651. Review.

16.

Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.

Josephs DH, Bax HJ, Lentfer H, Selkirk C, Spicer JF, Karagiannis SN.

Lancet. 2015 Feb 26;385 Suppl 1:S53. doi: 10.1016/S0140-6736(15)60368-3.

PMID:
26312875
17.

Mechanism of the antigen-independent cytokinergic SPE-7 IgE activation of human mast cells in vitro.

Bax HJ, Bowen H, Dodev TS, Sutton BJ, Gould HJ.

Sci Rep. 2015 Apr 20;5:9538. doi: 10.1038/srep09538.

18.

Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class.

Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM, Durham SR, Sutton BJ, Gould HJ, James LK.

Allergy. 2015 Jun;70(6):720-4. doi: 10.1111/all.12607. Epub 2015 Mar 28.

19.

Tumour-associated macrophage polarisation and re-education with immunotherapy.

Josephs DH, Bax HJ, Karagiannis SN.

Front Biosci (Elite Ed). 2015 Jan 1;7:293-308. Review.

PMID:
25553381
20.

A tool kit for rapid cloning and expression of recombinant antibodies.

Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, Bax HJ, Beavil R, Pang MO, Gould HJ, Karagiannis SN, Beavil AJ.

Sci Rep. 2014 Jul 30;4:5885. doi: 10.1038/srep05885.

21.

Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations.

Rice LV, Bax HJ, Russell LJ, Barrett VJ, Walton SE, Deakin AM, Thomson SA, Lucas F, Solari R, House D, Begg M.

Eur J Pharmacol. 2013 Mar 15;704(1-3):49-57. doi: 10.1016/j.ejphar.2013.02.022. Epub 2013 Feb 27.

PMID:
23454522
22.

Cytokinergic IgE Action in Mast Cell Activation.

Bax HJ, Keeble AH, Gould HJ.

Front Immunol. 2012 Aug 6;3:229. doi: 10.3389/fimmu.2012.00229. eCollection 2012.

23.

Mapping of the CD23 binding site on immunoglobulin E (IgE) and allosteric control of the IgE-Fc epsilonRI interaction.

Borthakur S, Hibbert RG, Pang MO, Yahya N, Bax HJ, Kao MW, Cooper AM, Beavil AJ, Sutton BJ, Gould HJ, McDonnell JM.

J Biol Chem. 2012 Sep 7;287(37):31457-61. doi: 10.1074/jbc.C112.397059. Epub 2012 Jul 19.

Supplemental Content

Support Center